GMT Capital Corp raised its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 5.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,267,700 shares of the biopharmaceutical company's stock after buying an additional 170,200 shares during the period. Royalty Pharma makes up about 4.1% of GMT Capital Corp's holdings, making the stock its 9th biggest holding. GMT Capital Corp owned approximately 0.55% of Royalty Pharma worth $83,359,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the business. Brooklyn Investment Group grew its holdings in Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 876 shares in the last quarter. Allworth Financial LP increased its holdings in Royalty Pharma by 417.6% in the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 877 shares during the last quarter. Riverview Trust Co increased its holdings in Royalty Pharma by 3,953.3% in the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,186 shares during the last quarter. Fifth Third Bancorp raised its stake in Royalty Pharma by 187.1% during the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 997 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 376 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.
Royalty Pharma Stock Performance
NASDAQ RPRX traded up $0.24 during trading hours on Monday, reaching $32.44. The company's stock had a trading volume of 1,419,369 shares, compared to its average volume of 3,252,638. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The business has a 50-day simple moving average of $32.52 and a 200 day simple moving average of $29.45. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The stock has a market cap of $18.70 billion, a PE ratio of 22.38, a PEG ratio of 2.31 and a beta of 0.50.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Equities research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.
Royalty Pharma Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $0.22 dividend. The ex-dividend date is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.71%. Royalty Pharma's dividend payout ratio (DPR) is presently 60.69%.
Analyst Ratings Changes
Separately, Citigroup reissued a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $42.50.
Check Out Our Latest Analysis on Royalty Pharma
Royalty Pharma Profile
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Further Reading
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
